Key result
MitraClip implantation significantly reduced mean left atrial V-wave from 46.67 to 21.67 mmHg (p=0.009) and improved MR grade in critically ill patients with refractory heart failure.
Why the study?
The role of MitraClip implantation in the treatment of critically ill patients with heart failure and severe functional mitral regurgitation is undetermined.
Does MitraClip implantation improve outcomes in critically ill patients with refractory heart failure and severe functional mitral regurgitation?
Population
6 critically ill patients with decompensated refractory heart failure and severe functional mitral regurgitation (4+)
Comparison
MitraClip implantation
Design
Single-center observational cohort study
Follow-up
1-year
Authors
Loading...
May support bailout MitraClip use in refractory HF with severe FMR; leaves open need for prospective trials.
Observational (n=6)
No
Does MitraClip implantation improve outcomes in critically ill patients with refractory heart failure and severe functional mitral regurgitation?
p-value: p=0.009
MitraClip therapy may be a feasible bail-out option for critically ill patients with refractory heart failure and severe functional mitral regurgitation, improving hemodynamics and facilitating weaning from intravenous and mechanical support.
Medvedovsky et al. (2019) conducted an observational in Decompensated refractory heart failure and severe functional mitral regurgitation (n=6). MitraClip implantation was evaluated on Reduction of mitral regurgitation and left atrial V-wave (p=0.009). MitraClip implantation significantly reduced mean left atrial V-wave from 46.67 to 21.67 mmHg (p=0.009) and improved MR grade in critically ill patients with refractory heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: